Stocks and Investing Stocks and Investing
Wed, March 2, 2022
Tue, March 1, 2022

David Lebowitz Initiated (ASND) at Strong Buy and Held Target at $187 on, Mar 1st, 2022


Published on 2024-10-27 19:54:09 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Initiated "Ascendis Pharma A/S" (ASND) at Strong Buy and Held Target at $187 on, Mar 1st, 2022.

David has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 4 analyists that currently disagree with David


  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
  • Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $176 on, Wednesday, December 8th, 2021
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021
Contributing Sources